|
Simple blood test could indicate higher risk for coronary event (PHILADELPHIA) - The study, part of the Women's Health Initiative (WHI), sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, was conducted in 40 centers nationwide and included 271 cases of...
Experts are warning that schools and universities may soon need to test students sitting exams for drugs, in much the same way that athletes are currently tested. They say brain improving drugs for diseases such as Alzheimer's are being used by healthy people to boost alertness and memory and if...
Ardea Biosciences, Inc. today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor candidate, RDEA806, demonstrating no reproductive toxicity. In addition, novel second-generation NNRTI, RDEA427, was selected as a development candidate for the potential treatment...
Posted on: Thursday, 22 May 2008, 09:01 CDT DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain...
Posted on: Thursday, 22 May 2008, 09:01 CDT Schering-Plough has announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infected with hepatitis C virus genotype 1. One study will be in previously...
SAN DIEGO, May 22 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today the appointment of Dr.
Romark Laboratories, L.C., a privately-owned biopharmaceutical company, announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. patients with chronic hepatitis C genotype 1 who...
Posted on: Thursday, 22 May 2008, 11:53 CDT Amgen (NASDAQ: AMGN) today posted to the company's Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The AmgenMED and Amgen Foundation grant and donation lists, as well as the guidelines...
A Separate Retrospective Analysis of US Employer Claims Suggests a Benefit of Anti-Tumor Necrosis Factor Therapies on Absenteeism Among Employees with Inflammatory Bowel Disease SAN DIEGO, May 20, 2008 /PRNewswire/ -- Data from a new analysis of the...
The abortion pill known as RU-486 Though the first documented medical abortion in the U.S. dates back to 1950, it wasn't until 2000 that the Food and Drug Administration approved the contentious medical-abortion drug, mifepristone (still commonly referred to by its clinical-trial designation,...
